Related News
Glaxo lung drug fails in huge study
Print Edition
GlaxoSmithKline鈥檚 inhaled medicine Breo failed to prolong life in patients with chronic respiratory disease in a high-stakes clinical trial of 16,500 people, torpedoing hopes of a sales boost for the drug.
Shares in Britain鈥檚 biggest drugmaker fell 1.5 percent yesterday, lagging a strong London market, in reaction to the news announced by the company and its partner Theravance on Tuesday. Theravance plunged 15 percent.
Investors had hoped the large study would increase sales for the medicine, potentially by billions of dollars, underpinning GSK鈥檚 all-important respiratory business in the face of increasing competition.
Breo was approved in 2013 for chronic obstructive pulmonary disease (COPD), a leading cause of death worldwide that is often referred to as smoker鈥檚 cough, but sales have been slow to take off.
While Breo did lower the risk of dying by 12.2 percent compared to placebo, the difference was not big enough to be deemed statistically significant.
Had it succeeded, Breo would have been the first drug to show a survival benefit in patients with COPD.
The drug also reduced the rate of decline in lung function and heart problems, but because Breo failed its main study goal, statistical significance could not be inferred for these or other secondary objectives. Serious adverse events were similar on Breo and placebo.
Nine years ago, a similar study with GSK鈥檚 older drug Advair, involving 6,100 patients, also narrowly failed.
Inhaled drugs such as Breo that combine a steroid and a long-acting beta agonist help patients breathe more easily but their effect on survival has been unclear.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
